Hepatotoxicity associated with ribociclib among breast cancer patients
Stefania Finnsdottir, Ásgerður Sverrisdóttir, Einar S. Björnsson
Abstract
CDK4/6 inhibitors combined with endocrine therapy (ET) have become standard treatment for endocrine receptor (ER) positive, Her-2 negative metastatic breast cancer. Three agents, palbociclib, riboc...
Topics & Concepts
MedicinePalbociclibMetastatic breast cancerEndocrine systemOncologyBreast cancerCancerInternal medicineGynecologyHormoneAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysChronic Lymphocytic Leukemia Research